N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC has announced that their total number of voting rights and shares in issue stands at 394,780,349, with all these being ordinary shares with no shares held in treasury. The figure is critical for shareholders to calculate changes or notifications in their company shareholdings as per FCA rules. The company specializes in developing Nuvec®, a novel delivery system for cancer treatments and vaccines and aims to monetize its advancements through partnerships, upfront and milestone payments, and eventual royalties.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
